Mandy Jongbloed1,2, Wouter T Leijte1, Catharina F M Linssen3, Bernadette G van den Hoogen4,5, Eric C M van Gorp4,5, Martijn D de Kruif1. 1. Department of Pulmonology, Zuyderland Hospital, Heerlen, The Netherlands. 2. Faculty of Health, Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands. 3. Department of Medical Microbiology, Zuyderland Hospital, Heerlen, The Netherlands. 4. Department of Viroscience, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands. 5. Department of Infectious Diseases, Erasmus MC University Medical Center Rotterdam, Rotterdam, The Netherlands.
Abstract
BACKGROUND: The first outbreak of coronavirus disease 2019 (COVID-19) occurred in March 2020 in Europe, which is normally the peak incidence period of human metapneumovirus (HMPV) infections, implying cocirculation and potentially causing competition between them. METHODS: We investigated differences in clinical characteristics and outcomes of HMPV infections in hospitalized patients before (January 2016-28 February, 2020) and HMPV and COVID-19 during part of the COVID-19 pandemic (28 February, 2020-1 April, 2020). RESULTS: A total of 239 HMPV patients and 303 COVID-19 patients were included. Incidence of HMPV peaked in March. Despite a 324% increase in HMPV testing during the COVID-19 outbreak, incidence of HMPV remained stable. Clinical characteristics showed 25 (11%) ICU admissions and 14 (6%) deaths. History of myocardial infarction, higher age and lower BMI were independently associated with increased 30-day mortality. Clinical characteristics of HMPV-infected patients did not differ between the non-COVID-19 period and the examined COVID-19 period except for length of hospital stay (7 vs. 5 days). HMPV infection and COVID-19 shared many clinical features but HMPV was associated with female gender, elderly patients and chronic conditions (COPD and chronic heart failure). Clinical outcomes did not differ between the viruses during the COVID-19 period. CONCLUSIONS: The clinical impact of HMPV infection did not change during the COVID-19 outbreak in terms of incidence and/or disease severity; hence, HMPV and SARS-CoV-2 are probably co-circulating independently. Despite the current clinical focus on the COVID-19 pandemic, clinicians should keep in mind that HMPV-infection may mimic COVID-19 and is also associated with serious adverse outcomes.
BACKGROUND: The first outbreak of coronavirus disease 2019 (COVID-19) occurred in March 2020 in Europe, which is normally the peak incidence period of human metapneumovirus (HMPV) infections, implying cocirculation and potentially causing competition between them. METHODS: We investigated differences in clinical characteristics and outcomes of HMPV infections in hospitalized patients before (January 2016-28 February, 2020) and HMPV and COVID-19 during part of the COVID-19 pandemic (28 February, 2020-1 April, 2020). RESULTS: A total of 239 HMPVpatients and 303 COVID-19patients were included. Incidence of HMPV peaked in March. Despite a 324% increase in HMPV testing during the COVID-19 outbreak, incidence of HMPV remained stable. Clinical characteristics showed 25 (11%) ICU admissions and 14 (6%) deaths. History of myocardial infarction, higher age and lower BMI were independently associated with increased 30-day mortality. Clinical characteristics of HMPV-infectedpatients did not differ between the non-COVID-19 period and the examined COVID-19 period except for length of hospital stay (7 vs. 5 days). HMPV infection and COVID-19 shared many clinical features but HMPV was associated with female gender, elderly patients and chronic conditions (COPD and chronic heart failure). Clinical outcomes did not differ between the viruses during the COVID-19 period. CONCLUSIONS: The clinical impact of HMPV infection did not change during the COVID-19 outbreak in terms of incidence and/or disease severity; hence, HMPV and SARS-CoV-2 are probably co-circulating independently. Despite the current clinical focus on the COVID-19 pandemic, clinicians should keep in mind that HMPV-infection may mimic COVID-19 and is also associated with serious adverse outcomes.
Entities:
Keywords:
COVID-19; HMPV; Human metapneumovirus; hospitalization; mortality; severe acute respiratory syndrome coronavirus 2
Authors: S F J Voncken; T M H Feron; S A J S Laven; U Karaca; K Beerhorst; P Klarenbeek; J M J A A Straetmans; G J de Vries; A A B Kolfoort-Otte; M D de Kruif Journal: Sleep Breath Date: 2021-09-24 Impact factor: 2.655
Authors: Hye Jin Shi; Nam Yee Kim; Sun Ah Eom; Myung Deok Kim-Jeon; Sung Suck Oh; Bag Sou Moon; Mun Ju Kwon; Joong Sik Eom Journal: J Korean Med Sci Date: 2022-05-30 Impact factor: 5.354
Authors: Cmhj Kivit; K Groen; M Jongbloed; Cfm Linssen; A van Loo; Ecm van Gorp; S van Nieuwkoop; Bg van den Hoogen; Md de Kruif Journal: J Infect Date: 2022-02-03 Impact factor: 38.637
Authors: Hanna Krumbein; Lara S Kümmel; Paraskevi C Fragkou; Clemens Thölken; Ben L Hünerbein; Rieke Reiter; Konstantinos A Papathanasiou; Harald Renz; Chrysanthi Skevaki Journal: Rev Med Virol Date: 2022-06-10 Impact factor: 11.043
Authors: Fanny Wai San Ko; Louis Ho Shing Lau; So Shan Ng; Terry Cheuk Fung Yip; Grace Lai Hung Wong; Ka Pang Chan; Tat On Chan; David Shu Cheong Hui Journal: Respirology Date: 2022-08-10 Impact factor: 6.175